No study has demonstrated that hormone replacement therapy (HRT) affects blood pressure (BP) measured by 24-h ambulatory blood pressure monitoring (ABPM) in Japanese postmenopausal women (PMW) with normotension or mild-to-moderate essential hypertension. In the present study, we examined the effects of
Introduction
Arterial blood pressure (BP) in women increases with age, especially in women over the age of 60 years (1) (2) (3) . This increase in BP is more accelerated in postmenopausal than in premenopausal women (2) . Menopause has been associated with an increase in BP (2, 4) and an increased BP response to mental stress (4) . However, it is still unclear whether these changes are due to estrogen withdrawal or aging (5) .
The effects of hormone replacement therapy (HRT) on BP in women (28), it is important to determine whether HRT raises or lowers BP in hypertensive or normotensive postmenopausal women. Assessment of 24-h ambulatory blood pressure monitoring (ABPM) provides more information concerning an individual's prevailing BP than conventional "office" BP measurements. In studies assessing the association between HRT and BP (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , the majority of subjects were Caucasian or African while a small number of individuals were Asian, especially Japanese. These studies have investigated the effect of HRT on BP based only on the use of office BP measurements in hypertensive or normotensive Japanese postmenopausal women (20) (21) (22) (23) (24) (25) . However, there are no 24-h ABPM data from Japanese postmenopausal women with hypertension or normotension treated with HRT. In the present study, we examined the effects of HRT on office BP and 24h ABPM in Japanese postmenopausal hypertensive and normotensive women.
Methods

Subjects
Ninety-seven Japanese postmenopausal women (mean age: 53.4 4.4 years; range: 46 to 61 years) volunteered to participate in this study. Each patient had experienced natural menopause for at least 1 year. Menopausal status was confirmed by a serum estradiol (E2) concentration 20 pg/ml and a serum follicle-stimulating hormone (FSH) concentration 40 mIU/ml. None had received hormonal therapy before enrollment or had any contraindications to such treatment. Before entering the study, each individual underwent physical and laboratory examinations, including a gynecologic evaluation and mammogram, 12-lead electrocardiogram, and echocardiogram. None of the women smoked, used caffeine, or had a history of diabetes mellitus, thyroid disease, cardiovascular disease, venous thromboembolism, liver disorders, unexplained vaginal bleeding, or a personal or family history of breast cancer. No patient underwent exercise or dietary therapy before the study. Individuals were told to maintain the same diet and lifestyle habits, particularly their sodium intake, during the investigation.
All hypertensive patients in this study were diagnosed as having mild-to-moderate essential hypertension (stage I and II) based on the guidelines of the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI) (29) . Normal blood pressure was defined as systolic (SBP) and diastolic blood pressures (DBP) 130/85 mmHg as measured in a sitting position on at least 3 different occasions.
The office BP of all of the hypertensive patients had been well-controlled using antihypertensive medications for at least 3 years. No changes to the antihypertensive therapy were made during the study period. Of these women, 11 were treated with angiotensin-converting enzyme (ACE) in-hibitors, 7 with α1-blockers, 14 with β-blockers, 38 with calcium antagonists, and 5 with diuretics. None of the normotensive subjects were receiving any medications. Written informed consent was obtained from each individual before participation. The study protocol was approved by the Ethics Committee of the Cardiovascular Hospital of Central Japan.
Subjects were divided into 4 groups: 31 hypertensive postmenopausal women (mean age: 54 4 years; range: 47 to 58 years) received HRT for 12 months (hypertensive HRT group), and 30 hypertensive postmenopausal women (mean age: 53 4 years; range: 48 to 61 years) did not want to receive HRT (hypertensive control group); 17 normotensive postmenopausal women (mean age: 53 4 years; range: 49 to 59 years) received HRT for 12 months (normotensive HRT group), and 19 normotensive postmenopausal volunteer women (mean age: 53 5 years; range: 46 to 61 years) did not receive HRT (normotensive control group).
Study Design
Except for the control patients, each subject received a daily oral dose of HRT [0.625 mg of conjugated equine estrogen (CEE) combined with 2.5 mg of medroxyprogesterone (MPA)] for 12 months. All subjects attended the HRT clinic at the Cardiovascular Hospital of Central Japan every month for physical examinations, and office BP and heart rate measurements. Before and 12 months after the start of HRT, blood samples were obtained and a 24-h ABPM was performed. Blood samples were obtained in the morning after a 12-h fast. Blood was drawn after the subjects had been in a supine, resting position for at least 30 min. After centrifuging the blood samples, the serum was stored at 80°C until the time of assay. Patients in the control groups also attended the Cardiovascular Hospital of Central Japan.
Physical Examination
Office BP and heart rate were measured after the subjects had rested quietly in a sitting position for at least 10 min. Blood pressure in the patient's right arm was measured three times with a mercury sphygmomanometer, and the mean of the three measurements was used in this study. Then, anthropometric characteristics were determined. Weight was measured to the nearest 0.1 kg and height to the nearest 0.5 cm. The body mass index (BMI) was also calculated.
Twenty-Four-Hour Ambulatory Blood Pressure Recording
Twenty-four-hour ambulatory blood pressure (ABP) was recorded using an automated portable device (DS-250 Ambulatory Blood Pressure Monitor; Nihon Seimitsu Sokki, Gunma, Japan). This device uses an oscillometer to determine SBP and DBP. The arm cuff is inflated automatically by a pump, and the BP is digitally recorded on the hard disk of a personal computer to which the device is connected. The arm cuff (12 cm in length, standard adult size) was positioned in the middle of the non-dominant arm covering the brachial artery above the antecubital fossa. The correct position for the cuff was confirmed when three SBP and DBP values were concordant ( 5 mmHg) with those obtained from the opposite arm with the standard sphygmomanometer.
The recorder was programmed to measure BP every 15 min between 6:00 AM and 11:00 PM (daytime period) and every 30 min between 11:00 PM and 6:00 AM (nighttime period). The patients were told to continue their usual daily activities, but to keep their arm still and parallel to the trunk during ABP measurements. All women were required to retire to bed by 11:00 PM and remain recumbent until 7:00 AM the next morning. At the completion of the 24-h recording, three BP values recorded with the automated device were compared once again with those determined simultaneously with the standard sphygmomanometer in order to ensure that the values remained within 5 mmHg. Mean SBP and DBP values for the daytime and nighttime periods were calculated as mean values of the hourly averages. The nocturnal fall in SBP was calculated as (Daytime SBP Nighttime SBP)/Daytime SBP. Based on the nocturnal fall in SBP, we classified hypertensive patients as dippers ( 10%) or nondippers ( 10%), as previously described by Kario et al. (30) . The results of 24-h ABP were analyzed by the same operator blinded to the HRT regimen.
Assays
Samples of venous blood were placed in polystyrene tubes containing sodium EDTA (1 mg/ml). The EDTA-containing tubes were chilled promptly in an ice bath, and the plasma was separated by centrifugation at 3,100 g and 4°C for 10 min. Serum was separated by centrifugation at 1,000 g at room temperature for 10 min. Samples were stored at 80°C until the time of assay. The serum concentrations of FSH and E2 were measured by radioimmunoassay using commercially available kits (Boehringer Mannheim, Mannheim, Germany).
Statistical Analysis
Data are presented as the means SD. Analysis of variance (ANOVA) was used to analyze differences between the four groups. The χ 2 test and Fisher's exact test were used to compare categorical data. The paired t-test was used to analyze differences between the values recorded at baseline and again at 12 months. All probability values were 2-tailed. A value of p 0.05 was considered statistically significant.
Results
The clinical characteristics of the HRT and the control groups with hypertension and with normotension before the study are summarized in Table 1 . Age, BMI, and height were not statistically different between these four subgroups.
Weight was significantly greater in the hypertensive control group than in the normotensive control group (p 0.05). The hypertensive HRT group and the hypertensive control group received similar antihypertensive therapies. Table 2 summarizes the hormone concentrations and office BP and heart rate both before and after the 12-month study period. At baseline, there were no significant differences in FSH or E2 between the various groups. The 12month FSH concentration was significantly lower and the 12-month E2 concentration significantly higher in the hypertensive and the normotensive HRT groups than in the hypertensive and the normotensive control groups at the same time point, respectively (p 0.05 for both). These findings confirm the patients' compliance with the regimen. Patients in the two control groups did not exhibit any changes in FSH or E2 concentration at 12 months compared to baseline. Office SBP, DBP, and mean BP at baseline and after 12 months of therapy were significantly higher in the hypertensive groups than in their normotensive counterparts, respectively (p 0.05 for all comparisons), but there were no significant differences in baseline or 12-month office heart rates between the groups. HRT did not change office SBP, DBP, mean BP, or heart rate in any group.
Twenty-four-hour ABP, ambulatory heart rate, and the proportion of nondippers before and after the 12-month period in each group are summarized in Table 3 . The 24-h ambulatory, daytime, and nighttime BP and heart rate did not change after 12 months in any group compared with the baseline values. The baseline and 12-month 24-h, daytime, and nighttime SBP were higher in the hypertensive HRT group than in the normotensive control group (p 0.05 for all comparisons). The baseline and the 12-month 24-h ambu- Values are presented as the means SD. p 0.05 vs. normotensive. HRT, hormone replacement therapy; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood pressure. latory and daytime SBP, DBP, and mean BP were significantly higher in the hypertensive control group than in the normotensive control group (p 0.05 for all comparisons). The baseline and the 12-month nighttime SBP and mean BP were significantly higher in the hypertensive control group than in the normotensive control group (p 0.05 for all comparisons). There were no significant differences between the baseline and 12-month values for other parameters between the groups. There were no significant differences in baseline and 12-month proportions of nondippers in any group.
Discussion
We here revealed for the first time that the most commonly used HRT in Japan (oral CEE combined with MPA) does not influence office BP or ABP in normotensive or mild-to-moderate essential hypertensive Japanese postmenopausal women. Furthermore, HRT does not alter the proportion of nondippers among hypertensive women. Comparing 24-h ABPM and conventional BP measurements, the use of ABPM might provide greater insight into the effects of HRT on BP in the postmenopausal population than the use of office BP. Ambulatory blood pressure is considered a better predictor of cardiovascular morbidity than standard BP measurements and avoids the risk of "white coat hypertension," which is less associated with cardiovascular morbidity (31, 32) . Echocardiographic left ventricular mass is greater in patients who have high nighttime ABP (33) . Many studies (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) have investigated the effects of oral or transdermal HRT on BP in normotensive or hypertensive postmenopausal women. In these studies, transdermal HRT reduced 24-h ambulatory (9, 15) , daytime (8, 10, 13, 14) , or nighttime BP (6, 7, 9, 10, 14) without reducing office BP. With respect to oral HRT, a few studies have shown that oral HRT decreases office BP (11, 16) and ABP (11, 12) . But most studies demonstrate that oral HRT does not reduce office BP (17) (18) (19) (20) (21) (22) (23) (24) (25) or ABP (16, 18) , which is in keeping with the results of the present study. In two studies (10, 15), a differential BP response to oral and transdermal estrogen has been described, demonstrating that transdermal HRT reduces ABP, but oral HRT does not affect office BP. A possible mechanism responsible for this finding is that oral estrogens increase hepatic expression of angiotensinogen (34, 35) . The hepatic effect of transdermally delivered estrogen, in which first liver passage effects are avoided, is less pronounced than that of oral estrogen, and no significant increase in the renin-substrate concentration has been observed (36, 37) . Therefore, the antihypertensive effect of HRT might be stronger in association with the use of transdermal estrogen. In the present study, the use of oral HRT did not change BP based on either office BP or ABP in postmenopausal women.
Many studies using oral CEE have demonstrated no change in office BP (17, (20) (21) (22) (23) (24) (25) or ABP (16, 18) . However, Harvey et al. (16) reported a reduction in office BP without an alteration in ABP, suggesting that there is a dose-response difference of CEE on BP. Specifically, the lower dose of CEE (0.3 mg/day) decreased only the office SBP and the middle dose (0.625 mg/day) decreased office SBP and DBP, but the higher dose (1.25 mg/day) did not change office BP. These results differ from our results showing that 0.625 mg/day of CEE did not change ABP. This may have been due to differences in body weight. Because the body weight of the postmenopausal women (mean: 67 kg) in Harvey's study was greater than that of the women (mean: 57 kg) in our study, the dose of CEE (0.625 mg/day) in the present study may be equivalent to a higher dose.
There are several potential mechanisms by which estrogen regulates BP via effects on the vascular and renin-angiotensin-aldosterone system. A variety of direct and indirect vasodilatory effects of estrogen on blood vessels have been reported. Estrogen increases prostacyclin production (38) , endothelium-dependent vasodilation (39) , calcium channel blockade (40) , and bradykinin production (20) (21) (22) . Previous studies using oral estrogen have demonstrated increases in plasma renin activity and aldosterone concentration, likely through a hepatic-induced increase in angiotensinogen production (34, 35) . Our previous study also showed increases in the plasma angiotensin II and bradykinin concentrations in hypertensive postmenopausal women, suggesting that an estrogen-induced increase in angiotensin II may be balanced by an increase in bradykinin to maintain BP (22) . The resulting BP induced by oral HRT in women may remain at least stable by means of balancing vasoconstricting and vasodilatory effects.
While assessing the effect of added progesterone on BP, Seely et al. (7) demonstrated that administration of transdermal estradiol, with or without progesterone, has a similar hypotensive effect, particularly on nighttime ABP. Progestins exert antagonistic effects to estrogens. Vasoconstrictive reactions in response to progestins may occur (41) , and may be one of the explanations for a rise in BP. However, these effects do not seem to be of clinical importance (17) . A further possible confounding factor in the present study concerns the ethnic variability in BP. African-American populations are at increased risk for developing essential hypertension compared with other ethnic groups (42) . Moreover, in rats with deoxycorticosterone acetate (DOCA)-salt hypertension, the arterial pressure rises more rapidly and reaches a higher level in male rats than in female rats. Furthermore, the time course for the development of hypertension is exacerbated by gonadectomy in female rats, suggesting that the differences in salt sensitivity may be related to endogenous gonadal hormones (43, 44) . In addition, Otsuka et al. (45) have also reported that the impaired pressure-natriuresis response of Dahl-Iwai salt-sensitive (DS) rats is blunted by ovariectomy. The blunted pressure-natriuresis relationship in DS rats after ovariectomy suggests that salt sensitivity increases in postmenopausal hypertensive women. Therefore, it is possible that the administration of estrogen might reduce salt sensitivity in postmenopausal hypertensive women. Be-cause salt sensitivity is lower in Japanese populations than in Caucasians and Africans (46) , we speculate that the effect of HRT on BP may be weaker in Japanese than in Caucasian and African patients, which may explain why HRT did not have any effect on BP in the present study.
Nondippers are more likely than dippers to suffer latent as well as overt hypertensive target-organ damage, including cerebrovascular disease, chronic heart disease, and renal damage (47) (48) (49) . Mercuro et al. (9) demonstrated that HRT can partially normalize a blunted nocturnal BP decline in postmenopausal hypertensive women. Butkevich et al. (50) also found that HRT is associated with a significant decrease in the proportion of nondippers in a population of hypertensive postmenopausal women. However, we found no change in the proportion of nondippers associated with HRT in hypertensive and normotensive postmenopausal women. Although the mechanisms by which HRT fails to normalize a blunted nocturnal BP decline is unclear, we speculate that the discrepancy might be dependent on the type, dose, and route of estrogen and progestogen therapy, as well as ethnic differences. Forty to fifty percent of all patients with essential hypertension have an impaired nocturnal decline in BP (9, 30, 50) . The proportions of nondippers in these previous studies are similar to that in the present study. It should be noted that no extreme dippers or reverse dippers were found in the present study.
Recent large well-controlled clinical trials, the Heart and Estrogen/Progenstin Replacement Study (HERS), the HERS follow-up study (HERS II), and the Women's Health Initiative Randomized Controlled Trial, could not show a reduction in the incidence of coronary heart disease in postmenopausal women receiving oral CEE plus MPA (51) (52) (53) . The HERS, HERS II, and Women's Health Initiative Randomized Controlled Trial used CEE (0.625 mg/day) and MPA (2.5 mg/day), which were the same type and dose of HRT as in the present study. The present study showed that HRT failed to worsen office BP and ABP in normotensive and hypertensive postmenopausal women. Therefore, HRT may not influence BP in hypertensive postmenopausal women whose BP has been well-controlled before HRT, as well as in normotensive postmenopausal women.
The present study has some limitations. First, the study was not designed as a double-blind randomized placebo study, and the number of subjects enrolled in the study was relatively small. Second, in the present study, most hypertensive patients were on medications such as ACE inhibitors, α1-blockers, β-blockers, calcium antagonists, and diuretics, which may complicate the interpretation of the results. Further studies are thus needed to clarify these points.
In conclusion, HRT did not influence office BP or ABP in mild-to-moderate essential hypertensive and normotensive Japanese postmenopausal women. In addition, HRT did not alter the proportion of the nondippers in hypertensive and normotensive women. With respect to BP, HRT might not be harmful in hypertensive postmenopausal women whose BP has been well-controlled before HRT, as well as in normotensive postmenopausal women.
